Tremelimumab
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-TREMELIMUMAB |
|---|---|
| Type | Drug |
| Aliases | ImjudoТремелімумаб |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-HCC |
| Sources | SRC-NCCN-HCC-2025 |
Drug Facts
| Class | Anti-CTLA-4 human IgG2 monoclonal antibody (ICI) |
|---|---|
| Mechanism | Blocks CTLA-4 — releases T-cell activation brake at priming phase (synergistic with PD-1/PD-L1 blockade). Single-dose STRIDE regimen with durvalumab in HCC. |
| Typical dosing | STRIDE: 300 mg IV single priming dose with durvalumab 1500 mg, then durvalumab mono q4w. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Warnings
- Severe and fatal irAEs (more frequent with CTLA-4 than PD-1)
Notes
CTLA-4 irAE pattern differs from PD-1: earlier onset, more colitis and hypophysitis. Single-priming-dose STRIDE regimen (300 mg tremelimumab once + durvalumab maintenance) has acceptable safety vs older Q4W tremelimumab schedules and superseded prior dosing in HCC. Monitor LFTs / TFTs / cortisol / lipase before each durvalumab maintenance dose; high-dose IV methylprednisolone for G3-4 irAE; permanent discontinuation for myocarditis or recurrent G3 irAE despite steroids. UA access via EAP AstraZeneca / cross-border / self-pay only — not on НСЗУ.
Used By
Contraindications
CI-PEMBROLIZUMAB-AUTOIMMUNE- CI-PEMBROLIZUMAB-AUTOIMMUNE
Regimens
REG-DURVA-TREME-STRIDE- Durvalumab + Tremelimumab (STRIDE)